Advertisement

Digestive Diseases and Sciences

, Volume 60, Issue 5, pp 1414–1423 | Cite as

Withdrawal of Long-Term Maintenance Treatment with Azathioprine Tends to Increase Relapse Risk in Patients with Crohn’s Disease

  • Heimo H. WenzlEmail author
  • Christian Primas
  • Gottfried Novacek
  • Alexander Teml
  • Anna Öfferlbauer-Ernst
  • Christoph Högenauer
  • Harald Vogelsang
  • Wolfgang Petritsch
  • Walter Reinisch
Original Article

Abstract

Background and Aim

Many patients with quiescent Crohn’s disease are maintained on long-term treatment with azathioprine (AZA), but controlled data are limited. We aimed to evaluate the efficacy of AZA therapy for more than 4 years to maintain clinical remission.

Methods

We performed a randomized double-blind placebo-controlled AZA withdrawal trial with a follow-up period of 24 months. Patients had to have continuous AZA therapy ≥4 years without exacerbation of disease during the 12 months before enrollment, and a Crohn’s disease activity index <150 at baseline. Patients were randomized to continue on AZA or switch to placebo. The primary endpoint was time to clinical relapse during follow-up.

Results

After inclusion of 52 patients, the trial was stopped prematurely due to slow recruitment. During the 2-year follow-up, clinical relapse occurred in 4 of 26 (15 %) patients on continued AZA and in 8 of 26 (31 %) patients on placebo. Time to clinical relapse averaged 22.3 months (95 % CI 20.6–24.0) on AZA and 19.2 months (95 % CI 16.4–22.1) on placebo (p = 0.20). According to life-table analysis, the proportion of patients in remission after 12 and 24 months was 96 ± 4 and 86 ± 7 % in patients receiving AZA versus 76 ± 8 and 68 ± 9 % in patients receiving placebo (month 12, p = 0.035; month 24, p = 0.30). A higher AZA dose at enrollment was an independent predictor for relapse (p < 0.05).

Conclusions

AZA withdrawal resulted in a significantly increased relapse risk after 1 year and a nonstatistically significant trend for relapse after 2 years. Our results are in line with previous observations.

Keywords

Crohn’s disease Immunomodulators Azathioprine Clinical trails 

Notes

Acknowledgments

We are thankful to GlaxoSmithKline, Vienna, Austria, for providing the study medication, case report forms, and patient diaries. Representatives of GlaxoSmithKline did not have any role in study design, protocol development, data analysis, data interpretation, writing of the manuscript, or in the decision to submit the manuscript. We thank Marieluise Harrer and Georgiana Prinz for their help in patient recruitment and data acquisition. There was no funding or other financial support for this work.

Conflicts of interest

None.

References

  1. 1.
    Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.CrossRefPubMedGoogle Scholar
  2. 2.
    Petritsch W, Fuchs S, Berghold A, et al. Incidence of inflammatory bowel disease in the province of Styria, Austria, from 1997 to 2007: a population-based study. J Crohn’s Colitis. 2013;7:58–69.CrossRefGoogle Scholar
  3. 3.
    Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol. 2010;3:31–42.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. 1995;37:674–678.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn Disease. A meta-analysis. Ann Intern Med. 1995;123:132–142.CrossRefPubMedGoogle Scholar
  7. 7.
    Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD000067. doi: 10.1002/14651858.CD000067.pub2.
  8. 8.
    Peyrin-Biroulet L, Deltrenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–2096.CrossRefPubMedGoogle Scholar
  9. 9.
    Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis. 2010;4:28–62.CrossRefGoogle Scholar
  10. 10.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–987.CrossRefPubMedGoogle Scholar
  11. 11.
    Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff A. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol. 1993;88:1198–1205.PubMedGoogle Scholar
  12. 12.
    Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohn’s Colitis. 2010;4:63–101.CrossRefGoogle Scholar
  13. 13.
    O’Donoghue DP, Dawson AM, Powel-Tuck K, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet. 1978;2:955–957.CrossRefPubMedGoogle Scholar
  14. 14.
    Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215–219.CrossRefPubMedGoogle Scholar
  15. 15.
    Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol. 1999;94:3254–3257.CrossRefPubMedGoogle Scholar
  16. 16.
    Vilien M, Dahlerup JF, Munck LK, Nørregaard P, Grønbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increased relapse rate the following year. Aliment Pharmacol Therap. 2004;19:1147–1152.CrossRefGoogle Scholar
  17. 17.
    Sokol H, Seksik P, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J. Current smoking, not duration of remission, delays Crohn’s disease relapse following azathioprine withdrawal. Inflamm Bowel Dis. 2010;16:362–363.CrossRefPubMedGoogle Scholar
  18. 18.
    Lémann M, Mary J-Y, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–1818.CrossRefPubMedGoogle Scholar
  19. 19.
    Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80–85.CrossRefPubMedGoogle Scholar
  20. 20.
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 years review. Gut. 2002;50:485–489.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Mantzaris GJ, Roussos A, Christidou A, et al. The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn’s disease. J Crohn’s Colitis. 2007;1:28–34.CrossRefGoogle Scholar
  22. 22.
    French H. Mark Dalzell A, Srinivasan R, El-Matary W. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn’s disease: a meta-analysis. Dig Dis Sci. 2011;56:1929–1936.CrossRefPubMedGoogle Scholar
  23. 23.
    Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.CrossRefPubMedGoogle Scholar
  24. 24.
    Sokol H, Beaugerie L, Maynadié M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–2071.CrossRefPubMedGoogle Scholar
  25. 25.
    Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–1628.CrossRefPubMedGoogle Scholar
  26. 26.
    Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081–1085.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.CrossRefPubMedGoogle Scholar
  29. 29.
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–649.CrossRefPubMedGoogle Scholar
  30. 30.
    Higgins PD. Who wants to take a thiopurine holiday? Am J Gastroenterol. 2011;106:556–558.CrossRefPubMedGoogle Scholar
  31. 31.
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018–1024.CrossRefPubMedGoogle Scholar
  32. 32.
    Camus M, Seksik P, Bourrier A, et al. Long-term outcome of patients with Crohn’s disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11:389–394.CrossRefPubMedGoogle Scholar
  33. 33.
    Holtmann M, Krummenaeur F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci. 2006;51:1516–1524.CrossRefPubMedGoogle Scholar
  34. 34.
    Best WR, Becktel JM, Singelton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology. 1979;77:843–846.PubMedGoogle Scholar
  35. 35.
    Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27–32.CrossRefPubMedGoogle Scholar
  36. 36.
    Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810.PubMedGoogle Scholar
  37. 37.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413.CrossRefPubMedGoogle Scholar
  38. 38.
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585–612.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Nyman M, Hansson I, Eriksson S. Long-term immunosuppressive treatment in Crohn’s disease. Scand J Gastroenterol. 1985;20:1197–1203.CrossRefPubMedGoogle Scholar
  40. 40.
    Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–869.PubMedGoogle Scholar
  41. 41.
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–713.CrossRefPubMedGoogle Scholar
  42. 42.
    Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:15–36.CrossRefPubMedGoogle Scholar
  43. 43.
    Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn’s disease. Aliment Pharmacol Ther. 2014;39:163–175.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Reinisch W, Angelberger S, Petritsch W, et al. International AZT-2 Study Group. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomized, double-blind, double-dummy, multicentre trial. Gut. 2010;59:752–759.CrossRefPubMedGoogle Scholar
  45. 45.
    Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119–130.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Heimo H. Wenzl
    • 1
    Email author
  • Christian Primas
    • 2
  • Gottfried Novacek
    • 2
  • Alexander Teml
    • 2
  • Anna Öfferlbauer-Ernst
    • 2
  • Christoph Högenauer
    • 1
  • Harald Vogelsang
    • 2
  • Wolfgang Petritsch
    • 1
  • Walter Reinisch
    • 2
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal MedicineMedical University of GrazGrazAustria
  2. 2.Division of Gastroenterology and Hepatology, Department of Internal Medicine IIIMedical University of ViennaViennaAustria

Personalised recommendations